FINWIRES · TerminalLIVE
FINWIRES

RBC Sees USD/CAD Range-Bound In Near Term, Gradual Decline Longer Term

By

-- RBC Capital Markets in its CAD Weekly Soundbites (Rates & FX) note on Friday said an "event-rich" week "largely came as expected", with a "steady fiscal profile", the Bank of Canada delivering a "modestly hawkish hold" and first-quarter GDP "continuing to track above potential".

The bank said the BoC's hawkish tilt reinforces its view for a gradual decline in USD/CAD in the long term. However, it added that recent BoC and Federal Reserve meetings suggest both will be on hold in the short term, leaving a range-bound bias on USD/CAD.

In its rates view, RBC said the expected BoC hold was delivered this week, but the balance of changes tilted hawkish. The BoC modestly upgraded its GDP profile, noted the expected absorption of excess slack and said the neutral range discussion was slanted higher, even though the 2.25%-3.25% range was left unchanged.

RBC said it maintains its long-held view that the base case is the BoC on hold in 2026, with hikes in 2027, but added that the chance of second-half hikes far exceeds the chance of a cut.

On foreign exchange, RBC said this week's marginally hawkish BoC tilt reinforces its longer-run view for a gradual move lower in USD/CAD into next year, partly conditional on the BoC shifting to hikes in 2027, with risk in the second half of 2026.

However, in the near term, the bank said it continues to see the pair range-bound, as central bank meetings suggest the BoC and the Fed are likely to be on hold in the coming months, keeping US-Canada rate differentials relatively stable. That should continue to act as a floor under USD/CAD, with the 1.3500 area seen as the bottom of the range.

RBC added that a weekly close below 1.3598 has reasserted the downtrend in USD/CAD and favours a re-test of this year's lows at 1.3526 and 1.3482.

"Below there, the September 2024 low at 1.3420 would come into view. Initial resistance is located at 1.3598 and 1.3661, followed by 1.3728, with rallies to the latter two levels viewed as a selling opportunity," said George Davis, chief technical strategist at RBC Capital Markets.

Related Articles

Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Illumina

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $161 from $140, 31x our 2026 EPS estimate (up to $5.18 from $5.13; 2027 estimate up to $5.89 from $5.81), a premium to ILMN's one-year historical forward average of 24x. We were encouraged by ex-China organic sales rising ~3.5% Y/Y in Q1, while adjusted operating margin rose 150 bps Y/Y to 21.9%. We look positively on recent Congressional action to modestly increase the National Institutes of Health (NIH) budget (~1%) rather than the dramatic cuts initially feared by investors, though ILMN's guidance implies continued pressure in academic end markets in 2026. Excluding China, sequencing consumables within research and applied was down 12% Y/Y in Q1, though clinical consumables sales rose 20% Y/Y. Positively, ILMN placed over 80 NovaSeq X instruments (up 20 Y/Y) during the quarter, indicating strong momentum.

$ILMN
Research

Research Alert: CFRA Maintains Hold Recommendation On Vale S.a.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our unchanged 12-month target price of USD18 is driven by an EV/EBITDA of 5.0x applied to our 2027 EBITDA estimate, above VALE's three-year average forward EV/EBITDA of 3.9x but below peers' average of 6.5x. We decrease our 2026 earnings per ADS estimate by BRL0.49 to BRL10.28 and our 2027 forecast by BRL0.45 to BRL10.52. Vale demonstrated robust operational performance in Q1 2026, with production records across multiple assets supporting 3% iron ore volume growth and double-digit gains in copper and nickel. However, cost pressures from BRL appreciation and higher oil prices pushed C1 costs to $23.6/t (+12% Y/Y), leading management to guide toward the upper end of 2026 cost guidance. Vale Base Metals is delivering significant value, with EBITDA more than doubling Y/Y. With expanded net debt at $17.8B and trending toward the midpoint of the $10B-$20B target range, management expressed confidence in distributing significant dividends and continuing buybacks through 2026 under current commodity prices.

$VALE
Research

Research Alert: CFRA Maintains Sell Rating On Shares Of Teradyne, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target by $15 to $252, 29x our 2027 EPS view, above TER's three-year average (~25x), as broadening AI upside offsets customer concentration risks. We raise our 2026 EPS by $1.08 to $6.98 and 2027's by $1.30 to $8.70. Q1 2026 was another great quarter, but Q2 guidance (sales +87% Y/Y) spooked the bulls by coming in only near expectations rather than significantly outperforming. We have long cautioned of a potential reversal of recent strength given major customers' order lumpiness, and with today's selloff, we think valuation is starting to come back down to earth as investors pencil in a more pronounced sequential decline in 2H 2026. TER has also officially won some merchant GPU business, but its early results ($50M of revenue expected in 2026) are a bit underwhelming and further share gains are not a guarantee, dampening some of TER's near-term upside. In the meantime, we still think the memory shortage adds risks to industry activity in 2H 2026 and 2027 that are not appropriately priced in.

$TER